Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

AIMS: This post hoc assessment evaluated the efficacy and safety of once‐daily, prandial glucagon‐like peptide‐1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (estimated glomerular filtration rate ≥90 mL/min), or mild (60‐89 mL/min) or moderate (30‐59...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanefeld, Markolf, Arteaga, Juan M., Leiter, Lawrence A., Marchesini, Giulio, Nikonova, Elena, Shestakova, Marina, Stager, William, Gómez‐Huelgas, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655920/
https://www.ncbi.nlm.nih.gov/pubmed/28449324
http://dx.doi.org/10.1111/dom.12986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655920/
https://www.ncbi.nlm.nih.gov/pubmed/28449324
http://dx.doi.org/10.1111/dom.12986

Ejemplares similares